LALPATHLAB - Dr. Lal Pathlabs Limited Share Price

Healthcare Services

₹3380.00-3.40(-0.10%)

Market Closed as of Aug 22, 2025, 15:30 IST

Select time range

Valuation
Market Cap	27.7 kCr
Price/Earnings (Trailing)	53.69
Price/Sales (Trailing)	10.53
EV/EBITDA	33.47
Price/Free Cashflow	52.8
MarketCap/EBT	42.23
Enterprise Value	27.4 kCr

Fundamentals
Revenue (TTM)	2.63 kCr
Rev. Growth (Yr)	12.1%
Earnings (TTM)	518.4 Cr
Earnings Growth (Yr)	24.3%

Profitability
Operating Margin	25%
EBT Margin	25%
Return on Equity	23.49%
Return on Assets	19.08%
Free Cashflow Yield	1.89%

Price to Sales Ratio

Latest reported: 11

Revenue (Last 12 mths)

Latest reported: 3 kCr

Net Income (Last 12 mths)

Latest reported: 518 Cr

Growth & Returns
Price Change 1W	3%
Price Change 1M	14.1%
Price Change 6M	26.2%
Price Change 1Y	1.5%
3Y Cumulative Return	10.7%
5Y Cumulative Return	12.2%
7Y Cumulative Return	19.2%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-303.1 Cr
Cash Flow from Operations (TTM)	568.8 Cr
Cash Flow from Financing (TTM)	-334 Cr
Cash & Equivalents	292.6 Cr
Free Cash Flow (TTM)	524.5 Cr
Free Cash Flow/Share (TTM)	62.61

Balance Sheet
Total Assets	2.72 kCr
Total Liabilities	510.3 Cr
Shareholder Equity	2.21 kCr
Current Assets	1.36 kCr
Current Liabilities	402.5 Cr
Net PPE	335.8 Cr
Inventory	36.1 Cr
Goodwill	548.1 Cr

Capital Structure & Leverage
Debt Ratio	0.00
Debt/Equity	0.00
Interest Coverage	30.23
Interest/Cashflow Ops	28.09

Dividend & Shareholder Returns
Dividend/Share (TTM)	24
Dividend Yield	0.74%
Shares Dilution (1Y)	0.40%
Shares Dilution (3Y)	0.50%

Risk & Volatility
Max Drawdown	-20.3%
Drawdown Prob. (30d, 5Y)	31.54%
Risk Level (5Y)	39.9%

Pros

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Size: Market Cap wise it is among the top 20% companies of india.

Smart Money: Smart money has been increasing their position in the stock.

Profitability: Very strong Profitability. One year profit margin are 20%.

Momentum: Stock price has a strong positive momentum. Stock is up 14.1% in last 30 days.

Balance Sheet: Strong Balance Sheet.

Cons

No major cons observed.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Dividend Yield	0.74%
Dividend/Share (TTM)	24
Shares Dilution (1Y)	0.40%
Earnings/Share (TTM)	61.57

Financial Health
Current Ratio	3.39
Debt/Equity	0.00

Technical Indicators
RSI (14d)	70.88
RSI (5d)	78.73
RSI (21d)	73.65
MACD Signal	Buy
Stochastic Oscillator Signal	Sell
Grufity Signal	Buy
RSI Signal	Sell
RSI5 Signal	Sell
RSI21 Signal	Sell
SMA 5 Signal	Buy
SMA 10 Signal	Buy
SMA 20 Signal	Buy
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Summary of Latest Earnings Report from Dr. Lal Pathlabs

Summary of Dr. Lal Pathlabs's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Earnings Outlook

Last updated:

In the Q1 FY26 earnings call, Dr. Lal PathLabs' management provided a positive outlook for the company, emphasizing growth opportunities driven by healthcare expansion in India. The management highlighted the following key points:

Healthcare Growth: The demand for healthcare services is increasing, with a projected shortfall of 2.4 million hospital beds. Government initiatives like Ayushman Bharat are expected to augment public and private investment in healthcare, leading to greater demand for quality diagnostic services.
Technological Advancements: The market for AI in healthcare is anticipated to grow to $1.6 billion by the end of 2025, driven by increased integration of digital health technologies, which enhance operational efficiency and patient outcomes.
Volume Growth: The company reported a 10.7% growth in sample volumes, totaling 23.4 million samples for the quarter. Patient volumes increased by 5.3%, reaching 7.6 million.
Financial Performance: Q1 FY26 revenue stood at Rs. 670 crore, marking an 11.3% increase from Rs. 602 crore last year. Profit after tax rose to Rs. 134 crore, reflecting a robust growth of 24.3% with a PAT margin of 20%.
Strategic Initiatives: The organization is focusing on expanding its network through the addition of labs and patient service centers. In FY25, 18 new labs were added, and a similar number is expected to be opened in FY26.
Service Portfolio Expansion: The management has launched 58 new tests this quarter, reinforcing its commitment to high-complexity testing and areas like genomics and allergy testing.
Outlook and Growth Strategy: The company is guided by three strategic pillars: volume-led growth through market expansion, operational excellence via digital transformation, and branding through quality and accessibility. Management is optimistic about sustaining volume-led growth while maintaining profitability.

These initiatives reflect the company's intent to adapt to changing market conditions and capitalize on the growing demand for diagnostic services in India.

Q&A Session

Last updated:

Major Questions and Answers from the Q&A Section

1. Karthik Chellappa: Did our volume growth benefit from any unseasonal trends, or is this a clean quarter?

Shankha Banerjee: Yes, the growth is mainly like-for-like compared to Q1 last year. Any impacts from unseasonal rains were minimal.

2. Karthik Chellappa: Is there any specific cost management contributing to gross margin expansion despite low realization growth?

Ved Prakash Goel: Realizations grew from Rs. 833 to Rs. 880, thanks to a favorable test mix, particularly from our SwasthFit portfolio, contributing to improved margins.

3. Karthik Chellappa: Should we expect margin compression later in the year as you reinvest in the brand and infrastructure?

Ved Prakash Goel: Correct, while current margins are at 28.7%, they may not be sustainable for the full year due to investments in the latter half.

4. Anshul Agrawal: Is our volume growth secular across regions or concentrated in specific areas?

Shankha Banerjee: The sample growth closely follows our overall revenue growth and remains fairly consistent across major geographies.

5. Prakash Kapadia: Will we expect revenue growth to accelerate in markets like Bangalore and Mumbai after launching reference labs?

Shankha Banerjee: Reference lab impacts take time. While our strategy is sound, revenue growth will build gradually rather than jump instantly.

6. Surya Patra: What is the potential for test per patient to rise higher based on current trends?

Shankha Banerjee: We do not have a target, but factors like SwasthFit acceptance and increasing clinician prescriptions support a continued rise in tests per patient.

7. Karan Vora: What challenges have you faced with the Suburban acquisition?

Shankha Banerjee: We faced issues transitioning collection models post-COVID. The IT transition is timely, aligning Suburban with our operational standards.

8. Aashita Jain: How do you see your strategy in West India evolving with the dual brand approach?

Shankha Banerjee: Our focus is on expanding in urban centers like Mumbai and Pune, with growth driven by both collection networks and potentially more lab additions.

9. Yogesh Soni: What are your growth prospects in the genomics market?

Shankha Banerjee: The genomics market is growing, and we are investing significantly to capture market share; however, exact revenue contributions are not being disclosed.

10. Aashita Jain: Can you provide any insights on your radiology growth strategy?

Shankha Banerjee: We are piloting some high-end radiology services, including CT and MRI, and will develop our business model for expansion at the appropriate time.

11. Aashita Jain: What tax rate should we expect in the coming years?

Ved Prakash Goel: We expect a stable tax rate of 25%-26% moving forward, barring any one-time impacts.

12. Aashita Jain: Are you revising your revenue growth guidance of 11%-12%?

Shankha Banerjee: No, we will maintain our guidance of 11%-12% revenue growth for the year.

These summaries reflect the key inquiries and management responses, providing detailed insights while adhering to character limits.

Share Holdings

Understand Dr. Lal Pathlabs ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
Arvind Lal	30.73%
Vandana Lal	19.2%
Invesco Oppenheimer International Growth Fund	3.51%
Uti-Flexi Cap Fund	2.4%
Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund	2.12%
Anjaneya Lal	2.02%
Archana Lal Erdmann	1.84%
Sbi Large & Midcap Fund	1.7%
Smallcap World Fund, Inc	1.59%
Life Insurance Corporation Of India	1.47%
The Brown Capital Management International Small Company Fund	1.37%
Sundaram Mutual Fund A/C Sundaram Mid Cap Fund	1.12%
Indus India Fund (Mauritius) Limited	1.04%
Tata Balanced Advantage Fund	1.04%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Is Dr. Lal Pathlabs Better than it's peers?

Detailed comparison of Dr. Lal Pathlabs against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
APOLLOHOSP	Apollo Hospitals Enterprises	1.02 LCr	21.99 kCr	+8.40%	+18.80%	64.74	4.48	-	-
FORTIS	Fortis Healthcare	71.24 kCr	8.16 kCr	+20.60%	+82.50%	81.99	8.73	-	-
METROPOLIS	Metropolis Healthcare	11.03 kCr	1.42 kCr	+13.30%	+5.90%	72	7.75	-	-
VIJAYA	Vijaya Diagnostic Centre	10.83 kCr	735.03 Cr	+4.70%	+27.80%	71.97	14.73	-	-
THYROCARE	Thyrocare Tech	7.25 kCr	739.32 Cr	+17.80%	+57.70%	68.1	9.81	-	-

Sector Comparison: LALPATHLAB vs Healthcare Services

Comprehensive comparison against sector averages

Comparative Metrics

LALPATHLAB metrics compared to Healthcare

Category	LALPATHLAB	Healthcare
PE	52.85	66.19
PS	10.36	7.75
Growth	11.3 %	9 %

Performance Comparison

LALPATHLAB vs Healthcare (2021 - 2025)

Key Insights

1. LALPATHLAB is among the Top 3 Healthcare Service Provider companies by market cap.
2. The company holds a market share of 33.3% in Healthcare Service Provider.
3. In last one year, the company has had an above average growth that other Healthcare Service Provider companies.

Income Statement for Dr. Lal Pathlabs

Consolidated figures (in Rs. Crores) / View Standalone Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	10.5%	2,461	2,227	2,017	2,087	1,581	1,330
Other Income	35.3%	93	69	42	52	51	55
Total Income	11.3%	2,555	2,296	2,059	2,140	1,633	1,385
Cost of Materials	6.9%	482	451	447	502	397	299
Employee Expense	13.7%	482	424	376	365	274	243
Finance costs	-25%	22	29	38	30	16	15
Depreciation and Amortization	-1.4%	142	144	150	108	77	73
Other expenses	8.2%	802	741	703	660	474	446
Total Expenses	7.8%	1,930	1,790	1,715	1,665	1,238	1,075
Profit Before exceptional items and Tax	23.6%	625	506	344	475	394	310
Total profit before tax	23.6%	625	506	344	475	394	310
Current tax	16.3%	172	148	108	126	102	84
Deferred tax	-598.3%	-39.5	-4.8	-5.1	-1.9	-4.2	-0.9
Total tax	-7.7%	132	143	103	125	98	83
Total profit (loss) for period	36%	492	362	241	350	296	228
Other comp. income net of taxes	-187.5%	-3.6	-0.6	1.6	-1.3	-0.8	-1.1
Total Comprehensive Income	35.2%	489	362	243	349	296	226
Earnings Per Share, Basic	36.7%	58.48	43.05	28.82	41.7	35.33	27.42
Earnings Per Share, Diluted	36.7%	58.4	42.98	28.74	41.57	35.25	27.37

Description	(%) Q/Q	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024
Revenue From Operations	11.1%	670	603	597	660	602	545
Other Income	8%	28	26	25	22	21	18
Total Income	11.2%	698	628	622	682	622	564
Cost of Materials	9.4%	129	118	117	127	119	109
Employee Expense	14.9%	132	115	126	124	117	105
Finance costs	-7.5%	4.7	5	5.3	6	6	6.6
Depreciation and Amortization	-2.9%	35	36	36	35	35	37
Other expenses	8%	216	200	199	206	196	186
Total Expenses	8.9%	517	475	484	499	473	444
Profit Before exceptional items and Tax	18.4%	181	153	138	183	150	120
Total profit before tax	18.4%	181	153	138	183	150	120
Current tax	15.8%	45	39	40	48	45	33
Deferred tax	102.6%	2.1	-41.4	0.7	3.9	-2.7	1.5
Total tax	1583.9%	47	-2.1	40	52	42	34
Total profit (loss) for period	-14.2%	134	156	98	131	108	86
Other comp. income net of taxes	47.2%	-0.9	-2.6	-0.1	-0.8	-0.1	-0.9
Total Comprehensive Income	-13.2%	133	153	98	130	108	85
Earnings Per Share, Basic	-15.3%	15.88	18.57	11.6	15.52	12.79	10.13
Earnings Per Share, Diluted	-15.3%	15.85	18.54	11.58	15.48	12.76	10.12

Standalone figures (in Rs. Crores) / View Consolidated Data

AnnualQuarterly

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	19.6%	2,352	1,967	1,769	1,873	1,490	1,274
Other Income	88.1%	112	60	47	53	51	58
Total Income	21.5%	2,463	2,027	1,816	1,926	1,542	1,331
Cost of Materials	16.4%	455	391	390	446	374	287
Employee Expense	25.9%	458	364	316	320	257	232
Finance costs	-19.2%	22	27	34	28	15	15
Depreciation and Amortization	77.3%	134	76	82	75	70	68
Other expenses	18.3%	772	653	603	596	452	427
Total Expenses	21.9%	1,842	1,511	1,425	1,466	1,168	1,028
Profit Before exceptional items and Tax	20.4%	621	516	391	459	374	303
Total profit before tax	20.4%	621	516	391	459	374	303
Current tax	18.2%	163	138	101	118	98	80
Deferred tax	-475.7%	-39.3	-6	-3	-2.7	-4.5	-0.7
Total tax	-6.1%	124	132	98	115	94	80
Total profit (loss) for period	29.5%	497	384	292	344	280	223
Other comp. income net of taxes	-253.8%	-3.6	-0.3	1.9	-1.3	-0.7	-1.1
Total Comprehensive Income	28.7%	494	384	294	343	279	222
Earnings Per Share, Basic	29.7%	59.7	46.25	35.28	41.61	33.93	27.09
Earnings Per Share, Diluted	29.7%	59.61	46.18	35.17	41.48	33.85	27.04

Description	(%) Q/Q	Jun-2025	Mar-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024
Revenue From Operations	11.1%	641	577	528	584	534	479
Other Income	4.2%	26	25	30	22	29	16
Total Income	10.8%	667	602	558	606	563	495
Cost of Materials	10.9%	123	111	102	110	105	95
Employee Expense	15.7%	126	109	110	107	101	90
Finance costs	-7.9%	4.5	4.8	4.8	5	5.5	5.9
Depreciation and Amortization	-5.9%	33	35	19	18	18	20
Other expenses	6.1%	209	197	171	182	173	164
Total Expenses	8.1%	495	458	406	423	402	374
Profit Before exceptional items and Tax	18.8%	172	145	151	183	161	120
Total profit before tax	18.8%	172	145	151	183	161	120
Current tax	8.1%	41	38	36	44	40	30
Deferred tax	102.8%	2.2	-41.5	0.2	3.9	-2.4	1
Total tax	1033.3%	43	-3.5	37	48	38	31
Total profit (loss) for period	-12.9%	129	148	114	135	123	90
Other comp. income net of taxes	45.7%	-0.9	-2.5	-0.2	-1.1	-0.1	-0.4
Total Comprehensive Income	-12.4%	128	146	114	134	123	89
Earnings Per Share, Basic	-13.6%	15.51	17.8	13.74	16.24	14.76	10.73
Earnings Per Share, Diluted	-13.6%	15.49	17.78	13.71	16.2	14.73	10.71

Balance Sheet for Dr. Lal Pathlabs

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022
Cash and cash equivalents	175.5%	293	107	361	120	264	51
Current investments	13.2%	327	289	114	110	150	124
Loans, current	-	1.1	1	1.3	1.2	1.4	1.1
Total current financial assets	4.2%	1,305	1,252	1,070	1,016	923	766
Inventories	-23.9%	36	47	37	41	34	54
Current tax assets	-	0	0	0	0	0	0
Total current assets	2.9%	1,364	1,326	1,127	1,079	973	835
Property, plant and equipment	2.4%	336	328	343	347	401	416
Capital work-in-progress	525%	3.5	1.4	4	9.8	3	6.6
Investment property	-3%	33	34	34	34	0	0
Goodwill	0%	548	548	548	548	548	555
Loans, non-current	-	0	0	0	0	0.1	0.1
Total non-current financial assets	220%	81	26	32	25	40	31
Total non-current assets	6.4%	1,353	1,272	1,329	1,366	1,412	1,467
Total assets	4.6%	2,717	2,598	2,456	2,445	2,386	2,302
Borrowings, non-current	-	0	0	0	42	83	125
Total non-current financial liabilities	6.2%	103	97	103	165	213	266
Provisions, non-current	-	1.9	0	0	0	0	0
Total non-current liabilities	8.1%	108	100	105	168	216	269
Borrowings, current	-102.4%	0	42	83	83	153	112
Total current financial liabilities	-15.6%	310	367	379	376	409	382
Provisions, current	17.2%	35	30	38	33	29	26
Current tax liabilities	-53.6%	14	29	13	25	0.5	14
Total current liabilities	-13%	402	462	465	471	470	450
Total liabilities	-9.3%	510	562	571	639	686	719
Equity share capital	0%	84	84	84	84	83	83
Non controlling interest	0%	34	34	36	34	33	33
Total equity	8.4%	2,206	2,035	1,885	1,806	1,700	1,583
Total equity and liabilities	4.6%	2,717	2,598	2,456	2,445	2,386	2,302

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022
Cash and cash equivalents	366.7%	267	58	326	89	220	21
Current investments	50.5%	302	201	70	93	141	96
Loans, current	100%	1	0.8	1.2	1	1.2	0.9
Total current financial assets	16.7%	1,224	1,049	874	839	772	607
Inventories	-13.9%	32	37	28	32	23	41
Current tax assets	-	0	0	0	0	0	0
Total current assets	14.7%	1,277	1,113	920	892	810	660
Property, plant and equipment	13.9%	321	282	294	296	345	357
Capital work-in-progress	525%	3.5	1.4	4	9.7	3	6.6
Investment property	-3%	33	34	34	34	0	0
Goodwill	469900%	471	1.1	1.1	1.1	1.1	1.1
Non-current investments	-89.5%	114	1,073	1,073	1,072	1,072	1,079
Loans, non-current	-	0	0	0	0	0.1	0.1
Total non-current financial assets	-82.1%	194	1,082	1,093	1,086	1,097	1,102
Total non-current assets	-8.3%	1,344	1,466	1,495	1,500	1,510	1,544
Total assets	1.6%	2,621	2,579	2,415	2,392	2,320	2,204
Borrowings, non-current	-	0	0	0	42	83	125
Total non-current financial liabilities	14.1%	98	86	91	152	198	248
Total non-current liabilities	14.1%	98	86	91	152	198	248
Borrowings, current	-102.4%	0	42	83	83	153	112
Total current financial liabilities	-10.2%	300	334	349	345	380	351
Provisions, current	57.1%	34	22	31	27	23	20
Current tax liabilities	-53.6%	14	29	13	25	0.5	14
Total current liabilities	-7.4%	388	419	424	430	432	410
Total liabilities	-3.6%	487	505	516	582	630	657
Equity share capital	0%	84	84	84	84	83	83
Total equity	2.9%	2,134	2,074	1,900	1,810	1,690	1,547
Total equity and liabilities	1.6%	2,621	2,579	2,415	2,392	2,320	2,204

Cash Flow for Dr. Lal Pathlabs

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-25%	22	29	38	30	-	-
Change in inventories	104.4%	1.2	-3.5	19	-10	-	-
Depreciation	-1.4%	142	144	150	108	-	-
Impairment loss / reversal	-	3.4	0	7.6	-1.3	-	-
Unrealised forex losses/gains	16.7%	0	-0.2	-0.4	0	-	-
Adjustments for interest income	20.4%	66	55	33	47	-	-
Share-based payments	23.8%	27	22	23	32	-	-
Net Cashflows from Operations	9.9%	733	667	562	577	-	-
Income taxes paid (refund)	24.4%	164	132	106	130	-	-
Net Cashflows From Operating Activities	6.4%	569	535	456	447	-	-
Cashflows used in obtaining control of subsidiaries	-66.7%	0	0.4	0	458	-	-
Proceeds from sales of PPE	-200%	0.7	0.9	0.5	1.6	-	-
Purchase of property, plant and equipment	-14%	44	51	36	94	-	-
Purchase of intangible assets	62.3%	9.6	6.3	8.1	382	-	-
Interest received	40.9%	63	45	31	50	-	-
Other inflows (outflows) of cash	-2208.8%	-313	-12.6	-256	436	-	-
Net Cashflows From Investing Activities	-1102%	-303.1	-24.3	-287.3	-449.2	-	-
Proceeds from issuing shares	-	13	0	0.9	0	-	-
Proceeds from exercise of stock options	-140%	0	3.5	0	0.2	-	-
Proceeds from borrowings	-	0	0	0	345	-	-
Repayments of borrowings	-46.1%	83	153	109	0	-	-
Payments of lease liabilities	0%	34	34	34	62	-	-
Dividends paid	3%	207	201	103	117	-	-
Interest paid	-25%	22	29	38	30	-	-
Other inflows (outflows) of cash	-	0	0	-0.1	0	-	-
Net Cashflows from Financing Activities	19.3%	-334	-413.9	-283.2	136	-	-
Net change in cash and cash eq.	-172.2%	-68.3	97	-114.5	134	-	-

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-19.2%	22	27	34	28	-	-
Change in inventories	92.3%	0.6	-4.2	16	-0.8	-	-
Depreciation	77.3%	134	76	82	75	-	-
Impairment loss / reversal	-	3	0	1.5	1.1	-	-
Dividend income	945.5%	24	3.2	12	1.6	-	-
Adjustments for interest income	36.4%	61	45	28	45	-	-
Share-based payments	30%	27	21	21	32	-	-
Net Cashflows from Operations	15.3%	695	603	527	541	-	-
Income taxes paid (refund)	24.2%	155	125	99	117	-	-
Net Cashflows From Operating Activities	13%	540	478	428	424	-	-
Cashflows used in obtaining control of subsidiaries	100%	1	0.8	22	942	-	-
Proceeds from sales of PPE	-50%	0.7	0.8	0	0.4	-	-
Purchase of property, plant and equipment	-4.5%	43	45	32	63	-	-
Proceeds from sales of investment property	-	0	0	0.1	0	-	-
Purchase of intangible assets	150%	9.5	4.4	6.3	5.5	-	-
Dividends received	945.5%	24	3.2	12	1.6	-	-
Interest received	62.9%	58	36	27	48	-	-
Other inflows (outflows) of cash	-886.8%	-321.6	42	-268.1	460	-	-
Net Cashflows From Investing Activities	-1048.4%	-293	32	-288.6	-448.5	-	-
Proceeds from issuing shares	-	13	0	0	0	-	-
Proceeds from exercise of stock options	-140%	0	3.5	0.9	0.1	-	-
Proceeds from borrowings	-	0	0	0	345	-	-
Repayments of borrowings	-46.1%	83	153	109	0	-	-
Payments of lease liabilities	18.5%	33	28	19	59	-	-
Dividends paid	0%	200	200	99	116	-	-
Interest paid	-19.2%	22	27	44	28	-	-
Other inflows (outflows) of cash	-	0	0	0.1	0	-	-
Net Cashflows from Financing Activities	19.5%	-324.8	-403.9	-270	142	-	-
Net change in cash and cash eq.	-175%	-77.8	106	-131	117	-	-

What does Dr. Lal Pathlabs Limited do?

Healthcare Service Provider•Healthcare•Small Cap

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs. The company was founded in 1949 and is based in Gurugram, India.

Industry Group:Healthcare Services

Employees:4,099

Website:www.lalpathlabs.com

LALPATHLAB - Dr. Lal Pathlabs Limited Share Price

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Risk & Volatility

Investor Care

Financial Health

Technical Indicators

Major Questions and Answers from the Q&A Section

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Dr. Lal Pathlabs Limited do?